M S Czuczman1, J P Leonard2, S Jung3, J L Johnson3, E D Hsi4, J C Byrd5, B D Cheson6. 1. Roswell Park Cancer Institute, Buffalo. Electronic address: Myron.czuczman@roswellpark.org. 2. Weill Medical College of Cornell University, New York. 3. CALGB Statistical Office, Duke University Medical Center, Durham. 4. Cleveland Clinic Foundation, Cleveland. 5. The Ohio State University, Columbus. 6. Lombardi Cancer Center, Georgetown University Hospital, Washington, USA.
Abstract
BACKGROUND: This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL). PATIENTS AND METHODS: Patients with previously untreated FL (grades 1, 2, 3a) received 4 weekly infusions of G + R, followed by an additional dose every 2 months four times. International Workshop Response Criteria were used to evaluate response. RESULTS: Sixty-one patients were treated and antibody infusions were well tolerated. The overall response rate (ORR) is 72.1% (95% confidence interval 59.2% to 82.9%): 47.6% complete response (CR)/unconfirmed complete response (CRu) and 24.6% partial response. At a median follow-up time of 4.3 years (range, 0.3-5.3 years) median progression-free survival (PFS) is 2.9 years. Notably, Follicular Lymphoma International Prognostic Index (FLIPI) correlated with ORR, CR rate, and PFS, and the low-risk FLIPI group (n = 12) achieved a 92% ORR, 75% CR/CRu rate, and 75% 3-year PFS. CONCLUSIONS: An extended induction schedule of G + R in previously untreated FL is well tolerated and appears particularly efficacious in those patients with low-risk FLIPI scores. In addition, this trial served as the initial platform for additional CALGB 'doublet' combination regimes of rituximab plus other novel targeted agents.
BACKGROUND: This phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL). PATIENTS AND METHODS: Patients with previously untreated FL (grades 1, 2, 3a) received 4 weekly infusions of G + R, followed by an additional dose every 2 months four times. International Workshop Response Criteria were used to evaluate response. RESULTS: Sixty-one patients were treated and antibody infusions were well tolerated. The overall response rate (ORR) is 72.1% (95% confidence interval 59.2% to 82.9%): 47.6% complete response (CR)/unconfirmed complete response (CRu) and 24.6% partial response. At a median follow-up time of 4.3 years (range, 0.3-5.3 years) median progression-free survival (PFS) is 2.9 years. Notably, Follicular Lymphoma International Prognostic Index (FLIPI) correlated with ORR, CR rate, and PFS, and the low-risk FLIPI group (n = 12) achieved a 92% ORR, 75% CR/CRu rate, and 75% 3-year PFS. CONCLUSIONS: An extended induction schedule of G + R in previously untreated FL is well tolerated and appears particularly efficacious in those patients with low-risk FLIPI scores. In addition, this trial served as the initial platform for additional CALGB 'doublet' combination regimes of rituximab plus other novel targeted agents.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: E Giné; S Montoto; F Bosch; L Arenillas; S Mercadal; N Villamor; A Martínez; L Colomo; E Campo; E Montserrat; A López-Guillermo Journal: Ann Oncol Date: 2006-08-28 Impact factor: 32.976
Authors: Thomas Relander; Nathalie A Johnson; Pedro Farinha; Joseph M Connors; Laurie H Sehn; Randy D Gascoyne Journal: J Clin Oncol Date: 2010-04-12 Impact factor: 44.544
Authors: Thomas E Witzig; Allen M Vukov; Thomas M Habermann; Susan Geyer; Paul J Kurtin; William R Friedenberg; William L White; Haji I Chalchal; Patrick J Flynn; Thomas R Fitch; Debra A Welker Journal: J Clin Oncol Date: 2005-01-18 Impact factor: 44.544
Authors: P Colombat; G Salles; N Brousse; P Eftekhari; P Soubeyran; V Delwail; E Deconinck; C Haïoun; C Foussard; C Sebban; A Stamatoullas; N Milpied; F Boué; B Taillan; P Lederlin; A Najman; C Thièblemont; F Montestruc; A Mathieu-Boué; A Benzohra; P Solal-Céligny Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: Christian Buske; Eva Hoster; Martin Dreyling; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2006-05-11 Impact factor: 22.113
Authors: A R Martin; D D Weisenburger; W C Chan; E I Ruby; J R Anderson; J M Vose; P J Bierman; M A Bast; D T Daley; J O Armitage Journal: Blood Date: 1995-06-15 Impact factor: 22.113
Authors: Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger Journal: Clin Cancer Res Date: 2015-09-30 Impact factor: 12.531
Authors: Sonali M Smith; Brandelyn N Pitcher; Sin-Ho Jung; Nancy L Bartlett; Nina Wagner-Johnston; Steven I Park; Kristy L Richards; Amanda F Cashen; Anthony Jaslowski; Scott E Smith; Bruce D Cheson; Eric Hsi; John P Leonard Journal: Lancet Haematol Date: 2017-03-15 Impact factor: 18.959
Authors: Juan Du; Sandra Lopez-Verges; Brandelyn N Pitcher; Jeffrey Johnson; Sin-Ho Jung; Lili Zhou; Katharine Hsu; Myron S Czuczman; Bruce Cheson; Lawrence Kaplan; Lewis L Lanier; Jeffrey M Venstrom Journal: Cancer Immunol Res Date: 2014-06-23 Impact factor: 11.151